SAN DIEGO, January 12, 2021 – Today, Primmune Therapeutics announced the close of its Series A financing round with the addition of $4.0 million from Bioqube Ventures, a European life sciences venture capital firm. This brings the total of the Series A financing raise...
Primmune received a Paycheck Protection Program (“PPP”) loan from Silicon Valley Bank on April 30, 2020. On November 4, 2020, Primmune paid its PPP loan in full.
SAN DIEGO, March 2, 2020 – Primmune Therapeutics today announced that it has raised $7 million in seed financing to support the development of novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonists for long-term systemic activation of innate...
Appleman JR, Webber SE. Pharmacodynamic response in vitro and in vivo of novel orally administered Toll-like Receptor 7 agonists for systemic immunotherapy of cancer. In: 34th Annual Meeting and Pre-conference Programs of the Society for Immunotherapy of Cancer (SITC...
